Key result
Universal cholesterol screening and early identification of genetic mutations in children with dyslipidemia provide an opportunity to prevent premature cardiovascular disease-related events.
Why the study?
Does screening for genetic mutations and cholesterol in children and adolescents with dyslipidemia improve early identification and prevent premature cardiovascular disease?
Does screening for genetic mutations and cholesterol in children and adolescents with dyslipidemia improve early identification and prevent premature cardiovascular disease?
Universal cholesterol screening and genetic testing in children and adolescents are crucial for early identification and management of dyslipidemia to prevent premature cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Supports early screening consideration in pediatric dyslipidemia; leaves open whether universal genetic testing prevents events.
Introduction: Disorders of lipid metabolism caused by genetic mutations, acquired risk factors and risk conditions, or both, are common in children. While some manifest clinical signs and symptoms, children with genetic mutations such as familial hypercholesterolemia are asymptomatic and generally of normal weight. Nonetheless, life-long elevation of cholesterol plays a key role in the initiation and progression of atherosclerosis, starting in childhood, and increases risk of premature cardiovascular disease-related events, such as myocardial infarction and stroke.Areas covered: Genetic mutations and acquired risk factors and conditions that cause dyslipidemia are outlined. Current guidelines for screening, interpretation of test results, implementation of therapy and monitoring are reviewed, and the role of genetic testing is discussed.Expert opinion: In addition to a heart healthy lifestyle, those with inherited disorders of lipid metabolism often benefit from timely medical intervention to reduce or postpone morbidity and avoid premature mortality. The ability to identify this vulnerable population creates the opportunity to prevent development of premature cardiovascular disease-related events by effective management of genetic and acquired risk factors. As universal cholesterol screening of children becomes standard practice, healthcare professionals need to be familiar with the care and follow-up of those at moderate to high risk.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2016) conducted a review in Dyslipidemia. Screening for genetic mutations was evaluated. Universal cholesterol screening and early identification of genetic mutations in children with dyslipidemia provide an opportunity to prevent premature cardiovascular disease-related events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: